ANACOR REPORTS INTERIM STUDY RESULTS FOR AN2690

A A

Anacor Pharmaceuticals has announced preliminary results from an ongoing open-label Phase II study demonstrating that AN2690, the first in a new class of antifungal agents, has potent clinical effects balanced with a favorable safety profile for the potential treatment of onychomycosis, a fungal infection of the nail and nail bed. This infection causes nails to deform, discolor and split.

The trial is assessing two doses of topical AN2690 — a 7.5 percent solution and a 5 percent solution — in 60 patients receiving once-daily treatment for 180 days.